Overview

Clostridium Butyricum CBM588 vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study

Status:
COMPLETED
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This retrospective, real-world, single-center clinical study aimed to evaluate the effectiveness of probiotic Clostridium butyricum CBM588 (Butirrisan) versus Rifaximin in the management of Symptomatic Uncomplicated Diverticular Disease (SUDD). Patients with diverticulosis and a history of mild-to-moderate diverticulitis were included, and their clinical outcomes were assessed using existing patient records. The study compared two treatment groups: Experimental Group: Clostridium butyricum CBM588 (Butirrisan) + fiber supplementation. Control Group: Rifaximin + fiber supplementation. The primary endpoint was the reduction in SUDD symptoms, evaluated using patient-reported outcomes. Secondary outcomes included assessment of safety, risk of surgery, and changes in abdominal pain frequency and severity.
Phase:
NA
Details
Lead Sponsor:
Dr. Amjad Khan
Collaborator:
San Giovanni Addolorata Hospital
Treatments:
Rifaximin
Tablets